This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Melitracen is a thioxanthene neuroleptic indicated in the treatment of anxiety, depression, and asthenia.
- Generic Name
- Melitracen
- DrugBank Accession Number
- DB13384
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental, Investigational
- Structure
Structure for Melitracen (DB13384)
- Weight
- Average: 291.438
Monoisotopic: 291.198699809 - Chemical Formula
- C21H25N
- Synonyms
- Melitracen
- Melitraceno
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to treat Anxiety Combination Product in combination with: Flupentixol (DB00875) •••••••••••• •••••• Used in combination to treat Depression Combination Product in combination with: Flupentixol (DB00875) •••••••••••• •••••• Used in combination to treat Schizophrenia and other psychotic disorders Combination Product in combination with: Flupentixol (DB00875) •••••••••••• •••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of CNS depression can be increased when 1,2-Benzodiazepine is combined with Melitracen. Acarbose Melitracen may decrease the hypoglycemic activities of Acarbose. Acebutolol Melitracen may decrease the antihypertensive activities of Acebutolol. Aceclofenac The risk or severity of gastrointestinal bleeding can be increased when Melitracen is combined with Aceclofenac. Acemetacin The risk or severity of gastrointestinal bleeding can be increased when Melitracen is combined with Acemetacin. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image ANXISET Melitracen (10 MG) + Flupentixol (0.5 MG) Tablet, film coated Oral บริษัท ยูเนียนเมดดิคอล (ประเทศไทย) จำกัด 2014-06-13 Not applicable Thailand 
DEANXIT Melitracen (10 MG) + Flupentixol (0.5 MG) Tablet, sugar coated Oral บริษัท บี.เอ็ล.ฮั้ว จำกัด 1985-02-13 Not applicable Thailand Deanxit - Filmtabletten Melitracen (10 mg) + Flupentixol (0.5 mg) Tablet, film coated Oral Lundbeck Austria Gmb H 1971-01-13 Not applicable Austria 
DEANXIT TABLET Melitracen (10 mg) + Flupentixol (0.5 mg) Tablet, film coated Oral LUNDBECK SINGAPORE PTE. LTD. 1988-09-05 Not applicable Singapore 
DORMIR TABLET, 20 ADET Melitracen (10 mg) + Flupentixol (0.5 mg) Tablet OSEL İLAÇ SAN. VE TİC. A.Ş. 2020-08-14 Not applicable Turkey 
Categories
- ATC Codes
- N06CA02 — Melitracen and psycholeptics
- N06CA — Antidepressants in combination with psycholeptics
- N06C — PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION
- N06 — PSYCHOANALEPTICS
- N — NERVOUS SYSTEM
- Drug Categories
- Agents that produce hypertension
- Agents that reduce seizure threshold
- Antidepressive Agents
- Antidepressive Agents, Tricyclic
- Central Nervous System Agents
- Central Nervous System Depressants
- Narrow Therapeutic Index Drugs
- Nervous System
- Neurotoxic agents
- Non-Selective Monoamine Reuptake Inhibitors
- Psychoanaleptics
- Psychotropic Drugs
- Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as anthracenes. These are organic compounds containing a system of three linearly fused benzene rings.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Anthracenes
- Sub Class
- Not Available
- Direct Parent
- Anthracenes
- Alternative Parents
- Trialkylamines / Organopnictogen compounds / Hydrocarbon derivatives
- Substituents
- Amine / Anthracene / Aromatic homopolycyclic compound / Hydrocarbon derivative / Organic nitrogen compound / Organonitrogen compound / Organopnictogen compound / Tertiary aliphatic amine / Tertiary amine
- Molecular Framework
- Aromatic homopolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Q7T0Y1109Z
- CAS number
- 5118-29-6
- InChI Key
- GWWLWDURRGNSRS-UHFFFAOYSA-N
- InChI
- InChI=1S/C21H25N/c1-21(2)19-13-7-5-10-17(19)16(12-9-15-22(3)4)18-11-6-8-14-20(18)21/h5-8,10-14H,9,15H2,1-4H3
- IUPAC Name
- [3-(10,10-dimethyl-9,10-dihydroanthracen-9-ylidene)propyl]dimethylamine
- SMILES
- CN(C)CCC=C1C2=CC=CC=C2C(C)(C)C2=CC=CC=C12
References
- General References
- FDA Thailand Product Information: Anxiset (melitracen/flupentixol) film-coated tablets [Link]
- External Links
- ChemSpider
- 23697
- BindingDB
- 112783
- 446248
- ChEBI
- 135214
- ChEMBL
- CHEMBL110094
- ZINC
- ZINC000001482101
- Wikipedia
- Melitracen
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Completed Treatment Compliance / Depression / Dyspepsia 1 4 Completed Treatment Emotional Disorders / Neurological Disorders 1 4 Completed Treatment Tinnitus 1 3 Completed Treatment Globus 1 1 Completed Treatment Healthy Men and Women 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet, sugar coated Oral Tablet Tablet Tablet, film coated Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00318 mg/mL ALOGPS logP 5.4 ALOGPS logP 4.95 Chemaxon logS -5 ALOGPS pKa (Strongest Basic) 9.76 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 1 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 3.24 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 116.42 m3·mol-1 Chemaxon Polarizability 36.16 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-0a4i-9070000000-a1b11cf6767a87110b94 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0007-0090000000-29a4b986e4bb3b5a0532 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0006-0090000000-d0c810d7f6105f5e1967 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0005-0090000000-88e45c17fc2caa64fbcb Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0006-0090000000-dbb90842e7b0b2dd93db Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-06di-1490000000-e6804aaddcf20e733f1a Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0gb9-0090000000-f65b81ca7f1d58043ce1 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 184.684326 predictedDarkChem Lite v0.1.0 [M-H]- 168.24065 predictedDeepCCS 1.0 (2019) [M+H]+ 185.698426 predictedDarkChem Lite v0.1.0 [M+H]+ 170.59863 predictedDeepCCS 1.0 (2019) [M+Na]+ 185.183126 predictedDarkChem Lite v0.1.0 [M+Na]+ 176.69176 predictedDeepCCS 1.0 (2019)
Drug created at June 23, 2017 20:41 / Updated at June 02, 2021 20:04